Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis.
Immunostimulating complexes (ISCOMs) are known to be highly effective adjuvants for envelope antigens of viral agents, but have not been evaluated for use with antigens of intracellular bacteria. Balb/c mice were subcutaneously immunized with ISCOMs into which the T cell-reactive membrane protein TUL4 of Francisella tularensis had been incorporated. Spleen cells from the immunized mice responded in vitro to TUL4 and to heat-killed F. tularensis live vaccine strain (LVS) with proliferation and production of gamma-interferon, whereas spleen cells from control mice immunized with TUL4 only did not respond to the antigens. When mice immunized with TUL4 ISCOMs were challenged with F. tularensis LVS, bacterial counts in spleen and liver were lower than in non-immunized mice. Again, TUL4 had no effect when used without ISCOMs. When proteins of a total membrane preparation of F. tularensis LVS were incorporated in ISCOMs and used for immunization, a decrease in bacterial counts was obtained which was similar in magnitude to that of TUL4 ISCOMs. Generally, the adjuvant effects demonstrated did not compare with the excellent protective effect of live tularaemia vaccine. Nonetheless, ISCOMs provide a means whereby protective antigens of F. tularensis can be tested.
Golovliov
I
I
Department of Infectious Diseases, University of Umeå, Sweden.
Ericsson
M
M
Akerblom
L
L
Sandström
G
G
Tärnvik
A
A
Sjöstedt
A
A
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000097:blood / Q000276:immunology; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology / Q000627:therapeutic use; D001426:Bacterial Proteins; D004269:DNA, Bacterial / Q000096:biosynthesis; D005604:Francisella tularensis / Q000276:immunology*; D016882:ISCOMs / Q000276:immunology* / Q000627:therapeutic use*; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D018796:Immunoconjugates / Q000276:immunology / Q000627:therapeutic use; D007371:Interferon-gamma / Q000096:biosynthesis; D008074:Lipoproteins / Q000276:immunology* / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D013601:T-Lymphocytes / Q000276:immunology*; D014406:Tularemia / Q000276:immunology / Q000517:prevention & control
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D001425:Bacterial Outer Membrane Proteins; D001426:Bacterial Proteins; D004269:DNA, Bacterial; D016882:ISCOMs; D018796:Immunoconjugates; D008074:Lipoproteins; C075214:TUL4 protein, Francisella tularensis; D007371:Interferon-gamma